nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—Lacosamide—epilepsy syndrome	0.499	1	CrCtD
Lisdexamfetamine—Lacosamide—Felbamate—epilepsy syndrome	0.062	0.199	CrCrCtD
Lisdexamfetamine—Phenacemide—Felbamate—epilepsy syndrome	0.042	0.135	CrCrCtD
Lisdexamfetamine—Aspartame—Lacosamide—epilepsy syndrome	0.0356	0.114	CrCrCtD
Lisdexamfetamine—L-Phenylalanine—Felbamate—epilepsy syndrome	0.031	0.0994	CrCrCtD
Lisdexamfetamine—Phenelzine—Lacosamide—epilepsy syndrome	0.0298	0.0954	CrCrCtD
Lisdexamfetamine—Phenacemide—Lacosamide—epilepsy syndrome	0.0241	0.0774	CrCrCtD
Lisdexamfetamine—Dextroamphetamine—Lacosamide—epilepsy syndrome	0.0234	0.0751	CrCrCtD
Lisdexamfetamine—Amphetamine—Lacosamide—epilepsy syndrome	0.0234	0.0751	CrCrCtD
Lisdexamfetamine—Methamphetamine—Lacosamide—epilepsy syndrome	0.0228	0.0729	CrCrCtD
Lisdexamfetamine—L-Phenylalanine—Lacosamide—epilepsy syndrome	0.0178	0.0571	CrCrCtD
Lisdexamfetamine—SLC6A2—locus ceruleus—epilepsy syndrome	0.0036	0.127	CbGeAlD
Lisdexamfetamine—SLC18A2—telencephalic ventricle—epilepsy syndrome	0.0028	0.0984	CbGeAlD
Lisdexamfetamine—SLC6A3—telencephalic ventricle—epilepsy syndrome	0.00212	0.0744	CbGeAlD
Lisdexamfetamine—SLC6A2—autonomic nervous system—epilepsy syndrome	0.00191	0.0673	CbGeAlD
Lisdexamfetamine—SLC18A2—ganglion—epilepsy syndrome	0.00174	0.0613	CbGeAlD
Lisdexamfetamine—SLC6A3—ganglion—epilepsy syndrome	0.00132	0.0463	CbGeAlD
Lisdexamfetamine—SLC6A2—ganglion—epilepsy syndrome	0.00106	0.0374	CbGeAlD
Lisdexamfetamine—SLC6A3—hindbrain—epilepsy syndrome	0.001	0.0351	CbGeAlD
Lisdexamfetamine—SLC18A2—brainstem—epilepsy syndrome	0.000757	0.0266	CbGeAlD
Lisdexamfetamine—SLC18A2—forebrain—epilepsy syndrome	0.000731	0.0257	CbGeAlD
Lisdexamfetamine—SLC18A2—telencephalon—epilepsy syndrome	0.000672	0.0236	CbGeAlD
Lisdexamfetamine—SLC6A3—brainstem—epilepsy syndrome	0.000573	0.0201	CbGeAlD
Lisdexamfetamine—SLC6A3—forebrain—epilepsy syndrome	0.000553	0.0194	CbGeAlD
Lisdexamfetamine—SLC18A2—medulla oblongata—epilepsy syndrome	0.000528	0.0186	CbGeAlD
Lisdexamfetamine—SLC6A3—telencephalon—epilepsy syndrome	0.000508	0.0179	CbGeAlD
Lisdexamfetamine—SLC18A2—midbrain—epilepsy syndrome	0.000483	0.017	CbGeAlD
Lisdexamfetamine—SLC6A2—brainstem—epilepsy syndrome	0.000462	0.0162	CbGeAlD
Lisdexamfetamine—SLC6A2—forebrain—epilepsy syndrome	0.000446	0.0157	CbGeAlD
Lisdexamfetamine—ADRA1B—head—epilepsy syndrome	0.000423	0.0149	CbGeAlD
Lisdexamfetamine—SLC18A2—head—epilepsy syndrome	0.000419	0.0147	CbGeAlD
Lisdexamfetamine—SLC6A2—telencephalon—epilepsy syndrome	0.00041	0.0144	CbGeAlD
Lisdexamfetamine—ADRA1B—nervous system—epilepsy syndrome	0.000401	0.0141	CbGeAlD
Lisdexamfetamine—SLC18A2—nervous system—epilepsy syndrome	0.000397	0.014	CbGeAlD
Lisdexamfetamine—Phenacemide—SCN1A—epilepsy syndrome	0.000388	0.164	CrCbGaD
Lisdexamfetamine—ADRA1B—central nervous system—epilepsy syndrome	0.000386	0.0136	CbGeAlD
Lisdexamfetamine—SLC18A2—central nervous system—epilepsy syndrome	0.000382	0.0134	CbGeAlD
Lisdexamfetamine—SLC18A2—cerebellum—epilepsy syndrome	0.000373	0.0131	CbGeAlD
Lisdexamfetamine—SLC6A3—midbrain—epilepsy syndrome	0.000365	0.0128	CbGeAlD
Lisdexamfetamine—SLC6A3—spinal cord—epilepsy syndrome	0.000356	0.0125	CbGeAlD
Lisdexamfetamine—Aspartame—TRPV1—epilepsy syndrome	0.000345	0.146	CrCbGaD
Lisdexamfetamine—SLC6A2—medulla oblongata—epilepsy syndrome	0.000322	0.0113	CbGeAlD
Lisdexamfetamine—SLC6A3—head—epilepsy syndrome	0.000317	0.0111	CbGeAlD
Lisdexamfetamine—ADRA1B—brain—epilepsy syndrome	0.000306	0.0108	CbGeAlD
Lisdexamfetamine—SLC18A2—brain—epilepsy syndrome	0.000303	0.0107	CbGeAlD
Lisdexamfetamine—SLC6A3—nervous system—epilepsy syndrome	0.0003	0.0106	CbGeAlD
Lisdexamfetamine—SLC6A3—central nervous system—epilepsy syndrome	0.000289	0.0102	CbGeAlD
Lisdexamfetamine—SLC6A3—cerebellum—epilepsy syndrome	0.000282	0.00993	CbGeAlD
Lisdexamfetamine—Lacosamide—SCN9A—epilepsy syndrome	0.000269	0.114	CrCbGaD
Lisdexamfetamine—Lacosamide—SCN3A—epilepsy syndrome	0.000257	0.109	CrCbGaD
Lisdexamfetamine—SLC6A2—head—epilepsy syndrome	0.000255	0.00898	CbGeAlD
Lisdexamfetamine—SLC6A2—nervous system—epilepsy syndrome	0.000242	0.00851	CbGeAlD
Lisdexamfetamine—Phenelzine—ABAT—epilepsy syndrome	0.000235	0.0992	CrCbGaD
Lisdexamfetamine—SLC6A2—central nervous system—epilepsy syndrome	0.000233	0.0082	CbGeAlD
Lisdexamfetamine—SLC6A3—brain—epilepsy syndrome	0.000229	0.00807	CbGeAlD
Lisdexamfetamine—SLC6A2—brain—epilepsy syndrome	0.000185	0.00651	CbGeAlD
Lisdexamfetamine—L-Phenylalanine—TH—epilepsy syndrome	0.000177	0.0748	CrCbGaD
Lisdexamfetamine—Lacosamide—CA4—epilepsy syndrome	0.000169	0.0716	CrCbGaD
Lisdexamfetamine—Methamphetamine—ADRA2A—epilepsy syndrome	5.69e-05	0.0241	CrCbGaD
Lisdexamfetamine—Labetalol—CYP2D6—epilepsy syndrome	5.45e-05	0.023	CrCbGaD
Lisdexamfetamine—Selegiline—CYP2C19—epilepsy syndrome	5.35e-05	0.0226	CrCbGaD
Lisdexamfetamine—Body temperature increased—Oxcarbazepine—epilepsy syndrome	5.24e-05	0.000507	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Fosphenytoin—epilepsy syndrome	5.24e-05	0.000507	CcSEcCtD
Lisdexamfetamine—Vomiting—Propofol—epilepsy syndrome	5.23e-05	0.000505	CcSEcCtD
Lisdexamfetamine—Rash—Propofol—epilepsy syndrome	5.18e-05	0.000501	CcSEcCtD
Lisdexamfetamine—Dermatitis—Propofol—epilepsy syndrome	5.18e-05	0.0005	CcSEcCtD
Lisdexamfetamine—Hypertension—Valproic Acid—epilepsy syndrome	5.17e-05	0.0005	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Gabapentin—epilepsy syndrome	5.15e-05	0.000498	CcSEcCtD
Lisdexamfetamine—Headache—Propofol—epilepsy syndrome	5.15e-05	0.000498	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Gabapentin—epilepsy syndrome	5.14e-05	0.000497	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Zonisamide—epilepsy syndrome	5.13e-05	0.000496	CcSEcCtD
Lisdexamfetamine—Vomiting—Midazolam—epilepsy syndrome	5.11e-05	0.000494	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Vigabatrin—epilepsy syndrome	5.11e-05	0.000494	CcSEcCtD
Lisdexamfetamine—Asthenia—Felbamate—epilepsy syndrome	5.11e-05	0.000494	CcSEcCtD
Lisdexamfetamine—Vision blurred—Pregabalin—epilepsy syndrome	5.1e-05	0.000493	CcSEcCtD
Lisdexamfetamine—Anxiety—Valproic Acid—epilepsy syndrome	5.08e-05	0.000491	CcSEcCtD
Lisdexamfetamine—Tremor—Pregabalin—epilepsy syndrome	5.07e-05	0.000491	CcSEcCtD
Lisdexamfetamine—Rash—Midazolam—epilepsy syndrome	5.07e-05	0.00049	CcSEcCtD
Lisdexamfetamine—Dizziness—Fosphenytoin—epilepsy syndrome	5.07e-05	0.00049	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Valproic Acid—epilepsy syndrome	5.07e-05	0.00049	CcSEcCtD
Lisdexamfetamine—Dermatitis—Midazolam—epilepsy syndrome	5.07e-05	0.00049	CcSEcCtD
Lisdexamfetamine—Urticaria—Carbamazepine—epilepsy syndrome	5.06e-05	0.000489	CcSEcCtD
Lisdexamfetamine—Lisinopril—ABCB1—epilepsy syndrome	5.05e-05	0.0213	CrCbGaD
Lisdexamfetamine—Vomiting—Levetiracetam—epilepsy syndrome	5.05e-05	0.000488	CcSEcCtD
Lisdexamfetamine—Headache—Midazolam—epilepsy syndrome	5.04e-05	0.000487	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Carbamazepine—epilepsy syndrome	5.03e-05	0.000487	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Diazepam—epilepsy syndrome	5.03e-05	0.000486	CcSEcCtD
Lisdexamfetamine—Rash—Levetiracetam—epilepsy syndrome	5.01e-05	0.000484	CcSEcCtD
Lisdexamfetamine—Dermatitis—Levetiracetam—epilepsy syndrome	5e-05	0.000484	CcSEcCtD
Lisdexamfetamine—Asthenia—Zonisamide—epilepsy syndrome	5e-05	0.000483	CcSEcCtD
Lisdexamfetamine—Mental disorder—Gabapentin—epilepsy syndrome	5e-05	0.000483	CcSEcCtD
Lisdexamfetamine—Dry mouth—Valproic Acid—epilepsy syndrome	4.99e-05	0.000482	CcSEcCtD
Lisdexamfetamine—Agitation—Pregabalin—epilepsy syndrome	4.98e-05	0.000481	CcSEcCtD
Lisdexamfetamine—Headache—Levetiracetam—epilepsy syndrome	4.97e-05	0.000481	CcSEcCtD
Lisdexamfetamine—Malnutrition—Gabapentin—epilepsy syndrome	4.97e-05	0.00048	CcSEcCtD
Lisdexamfetamine—Angioedema—Pregabalin—epilepsy syndrome	4.95e-05	0.000478	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Clonazepam—epilepsy syndrome	4.95e-05	0.000478	CcSEcCtD
Lisdexamfetamine—Dizziness—Vigabatrin—epilepsy syndrome	4.94e-05	0.000478	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Phenytoin—epilepsy syndrome	4.91e-05	0.000475	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Valproic Acid—epilepsy syndrome	4.89e-05	0.000473	CcSEcCtD
Lisdexamfetamine—Urticaria—Lamotrigine—epilepsy syndrome	4.89e-05	0.000473	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Oxcarbazepine—epilepsy syndrome	4.89e-05	0.000473	CcSEcCtD
Lisdexamfetamine—Nausea—Propofol—epilepsy syndrome	4.88e-05	0.000472	CcSEcCtD
Lisdexamfetamine—Vomiting—Fosphenytoin—epilepsy syndrome	4.87e-05	0.000471	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Felbamate—epilepsy syndrome	4.87e-05	0.000471	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Lamotrigine—epilepsy syndrome	4.86e-05	0.00047	CcSEcCtD
Lisdexamfetamine—Dizziness—Diazepam—epilepsy syndrome	4.86e-05	0.00047	CcSEcCtD
Lisdexamfetamine—Rash—Fosphenytoin—epilepsy syndrome	4.83e-05	0.000467	CcSEcCtD
Lisdexamfetamine—Dermatitis—Fosphenytoin—epilepsy syndrome	4.83e-05	0.000467	CcSEcCtD
Lisdexamfetamine—Nervousness—Gabapentin—epilepsy syndrome	4.82e-05	0.000466	CcSEcCtD
Lisdexamfetamine—Asthenia—Clonazepam—epilepsy syndrome	4.82e-05	0.000466	CcSEcCtD
Lisdexamfetamine—Headache—Fosphenytoin—epilepsy syndrome	4.8e-05	0.000464	CcSEcCtD
Lisdexamfetamine—Hepatitis—Topiramate—epilepsy syndrome	4.8e-05	0.000464	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Valproic Acid—epilepsy syndrome	4.8e-05	0.000464	CcSEcCtD
Lisdexamfetamine—Palpitations—Pregabalin—epilepsy syndrome	4.79e-05	0.000463	CcSEcCtD
Lisdexamfetamine—Asthenia—Phenytoin—epilepsy syndrome	4.79e-05	0.000463	CcSEcCtD
Lisdexamfetamine—Nausea—Midazolam—epilepsy syndrome	4.78e-05	0.000462	CcSEcCtD
Lisdexamfetamine—Hallucination—Topiramate—epilepsy syndrome	4.78e-05	0.000462	CcSEcCtD
Lisdexamfetamine—Tachycardia—Valproic Acid—epilepsy syndrome	4.77e-05	0.000461	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Zonisamide—epilepsy syndrome	4.77e-05	0.000461	CcSEcCtD
Lisdexamfetamine—Asthenia—Oxcarbazepine—epilepsy syndrome	4.76e-05	0.00046	CcSEcCtD
Lisdexamfetamine—Vomiting—Vigabatrin—epilepsy syndrome	4.75e-05	0.000459	CcSEcCtD
Lisdexamfetamine—Skin disorder—Valproic Acid—epilepsy syndrome	4.75e-05	0.000459	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Valproic Acid—epilepsy syndrome	4.73e-05	0.000457	CcSEcCtD
Lisdexamfetamine—Nausea—Levetiracetam—epilepsy syndrome	4.72e-05	0.000456	CcSEcCtD
Lisdexamfetamine—Phenelzine—CYP2C19—epilepsy syndrome	4.71e-05	0.0199	CrCbGaD
Lisdexamfetamine—Rash—Vigabatrin—epilepsy syndrome	4.71e-05	0.000455	CcSEcCtD
Lisdexamfetamine—Dizziness—Felbamate—epilepsy syndrome	4.71e-05	0.000455	CcSEcCtD
Lisdexamfetamine—Dermatitis—Vigabatrin—epilepsy syndrome	4.71e-05	0.000455	CcSEcCtD
Lisdexamfetamine—Convulsion—Pregabalin—epilepsy syndrome	4.69e-05	0.000454	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Carbamazepine—epilepsy syndrome	4.69e-05	0.000453	CcSEcCtD
Lisdexamfetamine—Amphetamine—SLC6A4—epilepsy syndrome	4.69e-05	0.0198	CrCbGaD
Lisdexamfetamine—Vision blurred—Gabapentin—epilepsy syndrome	4.68e-05	0.000452	CcSEcCtD
Lisdexamfetamine—Headache—Vigabatrin—epilepsy syndrome	4.68e-05	0.000452	CcSEcCtD
Lisdexamfetamine—Hypertension—Pregabalin—epilepsy syndrome	4.68e-05	0.000452	CcSEcCtD
Lisdexamfetamine—Vomiting—Diazepam—epilepsy syndrome	4.68e-05	0.000452	CcSEcCtD
Lisdexamfetamine—Anorexia—Valproic Acid—epilepsy syndrome	4.66e-05	0.000451	CcSEcCtD
Lisdexamfetamine—Tremor—Gabapentin—epilepsy syndrome	4.65e-05	0.00045	CcSEcCtD
Lisdexamfetamine—Rash—Diazepam—epilepsy syndrome	4.64e-05	0.000448	CcSEcCtD
Lisdexamfetamine—Dermatitis—Diazepam—epilepsy syndrome	4.63e-05	0.000448	CcSEcCtD
Lisdexamfetamine—Visual impairment—Topiramate—epilepsy syndrome	4.63e-05	0.000447	CcSEcCtD
Lisdexamfetamine—Dizziness—Zonisamide—epilepsy syndrome	4.61e-05	0.000445	CcSEcCtD
Lisdexamfetamine—Headache—Diazepam—epilepsy syndrome	4.61e-05	0.000445	CcSEcCtD
Lisdexamfetamine—Anxiety—Pregabalin—epilepsy syndrome	4.6e-05	0.000444	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Clonazepam—epilepsy syndrome	4.59e-05	0.000444	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	4.58e-05	0.000443	CcSEcCtD
Lisdexamfetamine—Asthenia—Carbamazepine—epilepsy syndrome	4.57e-05	0.000442	CcSEcCtD
Lisdexamfetamine—Agitation—Gabapentin—epilepsy syndrome	4.56e-05	0.000441	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Phenytoin—epilepsy syndrome	4.56e-05	0.000441	CcSEcCtD
Lisdexamfetamine—Nausea—Fosphenytoin—epilepsy syndrome	4.55e-05	0.00044	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Oxcarbazepine—epilepsy syndrome	4.54e-05	0.000439	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Topiramate—epilepsy syndrome	4.54e-05	0.000439	CcSEcCtD
Lisdexamfetamine—Angioedema—Gabapentin—epilepsy syndrome	4.54e-05	0.000439	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Lamotrigine—epilepsy syndrome	4.53e-05	0.000438	CcSEcCtD
Lisdexamfetamine—Vomiting—Felbamate—epilepsy syndrome	4.53e-05	0.000437	CcSEcCtD
Lisdexamfetamine—Dry mouth—Pregabalin—epilepsy syndrome	4.51e-05	0.000436	CcSEcCtD
Lisdexamfetamine—Rash—Felbamate—epilepsy syndrome	4.49e-05	0.000434	CcSEcCtD
Lisdexamfetamine—Eye disorder—Topiramate—epilepsy syndrome	4.49e-05	0.000434	CcSEcCtD
Lisdexamfetamine—Dermatitis—Felbamate—epilepsy syndrome	4.48e-05	0.000433	CcSEcCtD
Lisdexamfetamine—Headache—Felbamate—epilepsy syndrome	4.46e-05	0.000431	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Topiramate—epilepsy syndrome	4.45e-05	0.000431	CcSEcCtD
Lisdexamfetamine—Dizziness—Clonazepam—epilepsy syndrome	4.44e-05	0.000429	CcSEcCtD
Lisdexamfetamine—Nausea—Vigabatrin—epilepsy syndrome	4.44e-05	0.000429	CcSEcCtD
Lisdexamfetamine—Vomiting—Zonisamide—epilepsy syndrome	4.43e-05	0.000428	CcSEcCtD
Lisdexamfetamine—Insomnia—Valproic Acid—epilepsy syndrome	4.42e-05	0.000428	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Pregabalin—epilepsy syndrome	4.42e-05	0.000427	CcSEcCtD
Lisdexamfetamine—Asthenia—Lamotrigine—epilepsy syndrome	4.41e-05	0.000427	CcSEcCtD
Lisdexamfetamine—Dizziness—Phenytoin—epilepsy syndrome	4.41e-05	0.000426	CcSEcCtD
Lisdexamfetamine—Rash—Zonisamide—epilepsy syndrome	4.39e-05	0.000425	CcSEcCtD
Lisdexamfetamine—Palpitations—Gabapentin—epilepsy syndrome	4.39e-05	0.000424	CcSEcCtD
Lisdexamfetamine—Dermatitis—Zonisamide—epilepsy syndrome	4.39e-05	0.000424	CcSEcCtD
Lisdexamfetamine—Dizziness—Oxcarbazepine—epilepsy syndrome	4.39e-05	0.000424	CcSEcCtD
Lisdexamfetamine—Nausea—Diazepam—epilepsy syndrome	4.37e-05	0.000422	CcSEcCtD
Lisdexamfetamine—Headache—Zonisamide—epilepsy syndrome	4.36e-05	0.000422	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Valproic Acid—epilepsy syndrome	4.36e-05	0.000421	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Carbamazepine—epilepsy syndrome	4.36e-05	0.000421	CcSEcCtD
Lisdexamfetamine—Somnolence—Valproic Acid—epilepsy syndrome	4.35e-05	0.00042	CcSEcCtD
Lisdexamfetamine—Methamphetamine—SLC6A4—epilepsy syndrome	4.34e-05	0.0184	CrCbGaD
Lisdexamfetamine—Immune system disorder—Topiramate—epilepsy syndrome	4.34e-05	0.000419	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Pregabalin—epilepsy syndrome	4.33e-05	0.000419	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Topiramate—epilepsy syndrome	4.33e-05	0.000418	CcSEcCtD
Lisdexamfetamine—Tachycardia—Pregabalin—epilepsy syndrome	4.31e-05	0.000417	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Valproic Acid—epilepsy syndrome	4.3e-05	0.000416	CcSEcCtD
Lisdexamfetamine—Convulsion—Gabapentin—epilepsy syndrome	4.3e-05	0.000416	CcSEcCtD
Lisdexamfetamine—Skin disorder—Pregabalin—epilepsy syndrome	4.29e-05	0.000415	CcSEcCtD
Lisdexamfetamine—Hypertension—Gabapentin—epilepsy syndrome	4.29e-05	0.000415	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Pregabalin—epilepsy syndrome	4.27e-05	0.000413	CcSEcCtD
Lisdexamfetamine—Vomiting—Clonazepam—epilepsy syndrome	4.27e-05	0.000413	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Valproic Acid—epilepsy syndrome	4.25e-05	0.000411	CcSEcCtD
Lisdexamfetamine—Vomiting—Phenytoin—epilepsy syndrome	4.24e-05	0.00041	CcSEcCtD
Lisdexamfetamine—Rash—Clonazepam—epilepsy syndrome	4.23e-05	0.000409	CcSEcCtD
Lisdexamfetamine—Dermatitis—Clonazepam—epilepsy syndrome	4.23e-05	0.000409	CcSEcCtD
Lisdexamfetamine—Nausea—Felbamate—epilepsy syndrome	4.23e-05	0.000409	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	4.22e-05	0.000408	CcSEcCtD
Lisdexamfetamine—Vomiting—Oxcarbazepine—epilepsy syndrome	4.22e-05	0.000408	CcSEcCtD
Lisdexamfetamine—Fatigue—Valproic Acid—epilepsy syndrome	4.22e-05	0.000408	CcSEcCtD
Lisdexamfetamine—Anxiety—Gabapentin—epilepsy syndrome	4.21e-05	0.000407	CcSEcCtD
Lisdexamfetamine—Anorexia—Pregabalin—epilepsy syndrome	4.21e-05	0.000407	CcSEcCtD
Lisdexamfetamine—Dizziness—Carbamazepine—epilepsy syndrome	4.21e-05	0.000407	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Lamotrigine—epilepsy syndrome	4.21e-05	0.000407	CcSEcCtD
Lisdexamfetamine—Headache—Clonazepam—epilepsy syndrome	4.21e-05	0.000407	CcSEcCtD
Lisdexamfetamine—Rash—Phenytoin—epilepsy syndrome	4.21e-05	0.000407	CcSEcCtD
Lisdexamfetamine—Mental disorder—Topiramate—epilepsy syndrome	4.21e-05	0.000407	CcSEcCtD
Lisdexamfetamine—Dermatitis—Phenytoin—epilepsy syndrome	4.2e-05	0.000406	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	4.2e-05	0.000406	CcSEcCtD
Lisdexamfetamine—Rash—Oxcarbazepine—epilepsy syndrome	4.18e-05	0.000404	CcSEcCtD
Lisdexamfetamine—Constipation—Valproic Acid—epilepsy syndrome	4.18e-05	0.000404	CcSEcCtD
Lisdexamfetamine—Dermatitis—Oxcarbazepine—epilepsy syndrome	4.18e-05	0.000404	CcSEcCtD
Lisdexamfetamine—Headache—Phenytoin—epilepsy syndrome	4.18e-05	0.000404	CcSEcCtD
Lisdexamfetamine—Malnutrition—Topiramate—epilepsy syndrome	4.18e-05	0.000404	CcSEcCtD
Lisdexamfetamine—Headache—Oxcarbazepine—epilepsy syndrome	4.16e-05	0.000402	CcSEcCtD
Lisdexamfetamine—Nausea—Zonisamide—epilepsy syndrome	4.14e-05	0.0004	CcSEcCtD
Lisdexamfetamine—Dry mouth—Gabapentin—epilepsy syndrome	4.14e-05	0.0004	CcSEcCtD
Lisdexamfetamine—Dextroamphetamine—CYP2D6—epilepsy syndrome	4.09e-05	0.0173	CrCbGaD
Lisdexamfetamine—Dizziness—Lamotrigine—epilepsy syndrome	4.07e-05	0.000393	CcSEcCtD
Lisdexamfetamine—Nervousness—Topiramate—epilepsy syndrome	4.06e-05	0.000392	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Gabapentin—epilepsy syndrome	4.05e-05	0.000392	CcSEcCtD
Lisdexamfetamine—Vomiting—Carbamazepine—epilepsy syndrome	4.05e-05	0.000391	CcSEcCtD
Lisdexamfetamine—Rash—Carbamazepine—epilepsy syndrome	4.01e-05	0.000388	CcSEcCtD
Lisdexamfetamine—Dermatitis—Carbamazepine—epilepsy syndrome	4.01e-05	0.000388	CcSEcCtD
Lisdexamfetamine—Insomnia—Pregabalin—epilepsy syndrome	4e-05	0.000386	CcSEcCtD
Lisdexamfetamine—Nausea—Clonazepam—epilepsy syndrome	3.99e-05	0.000386	CcSEcCtD
Lisdexamfetamine—Headache—Carbamazepine—epilepsy syndrome	3.99e-05	0.000386	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Gabapentin—epilepsy syndrome	3.98e-05	0.000384	CcSEcCtD
Lisdexamfetamine—Selegiline—CYP2D6—epilepsy syndrome	3.96e-05	0.0167	CrCbGaD
Lisdexamfetamine—Nausea—Phenytoin—epilepsy syndrome	3.96e-05	0.000383	CcSEcCtD
Lisdexamfetamine—Tachycardia—Gabapentin—epilepsy syndrome	3.96e-05	0.000382	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Pregabalin—epilepsy syndrome	3.94e-05	0.000381	CcSEcCtD
Lisdexamfetamine—Nausea—Oxcarbazepine—epilepsy syndrome	3.94e-05	0.000381	CcSEcCtD
Lisdexamfetamine—Vision blurred—Topiramate—epilepsy syndrome	3.94e-05	0.000381	CcSEcCtD
Lisdexamfetamine—Skin disorder—Gabapentin—epilepsy syndrome	3.94e-05	0.000381	CcSEcCtD
Lisdexamfetamine—Somnolence—Pregabalin—epilepsy syndrome	3.93e-05	0.00038	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Gabapentin—epilepsy syndrome	3.92e-05	0.000379	CcSEcCtD
Lisdexamfetamine—Tremor—Topiramate—epilepsy syndrome	3.91e-05	0.000378	CcSEcCtD
Lisdexamfetamine—Vomiting—Lamotrigine—epilepsy syndrome	3.91e-05	0.000378	CcSEcCtD
Lisdexamfetamine—Urticaria—Valproic Acid—epilepsy syndrome	3.88e-05	0.000376	CcSEcCtD
Lisdexamfetamine—Rash—Lamotrigine—epilepsy syndrome	3.88e-05	0.000375	CcSEcCtD
Lisdexamfetamine—Dermatitis—Lamotrigine—epilepsy syndrome	3.88e-05	0.000375	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Valproic Acid—epilepsy syndrome	3.87e-05	0.000374	CcSEcCtD
Lisdexamfetamine—Anorexia—Gabapentin—epilepsy syndrome	3.86e-05	0.000374	CcSEcCtD
Lisdexamfetamine—Headache—Lamotrigine—epilepsy syndrome	3.85e-05	0.000373	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Pregabalin—epilepsy syndrome	3.84e-05	0.000371	CcSEcCtD
Lisdexamfetamine—Agitation—Topiramate—epilepsy syndrome	3.84e-05	0.000371	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	3.82e-05	0.000369	CcSEcCtD
Lisdexamfetamine—Fatigue—Pregabalin—epilepsy syndrome	3.81e-05	0.000368	CcSEcCtD
Lisdexamfetamine—Nausea—Carbamazepine—epilepsy syndrome	3.78e-05	0.000366	CcSEcCtD
Lisdexamfetamine—Constipation—Pregabalin—epilepsy syndrome	3.78e-05	0.000365	CcSEcCtD
Lisdexamfetamine—Palpitations—Topiramate—epilepsy syndrome	3.69e-05	0.000357	CcSEcCtD
Lisdexamfetamine—Insomnia—Gabapentin—epilepsy syndrome	3.67e-05	0.000354	CcSEcCtD
Lisdexamfetamine—Nausea—Lamotrigine—epilepsy syndrome	3.65e-05	0.000353	CcSEcCtD
Lisdexamfetamine—Convulsion—Topiramate—epilepsy syndrome	3.62e-05	0.00035	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Gabapentin—epilepsy syndrome	3.61e-05	0.000349	CcSEcCtD
Lisdexamfetamine—Hypertension—Topiramate—epilepsy syndrome	3.61e-05	0.000349	CcSEcCtD
Lisdexamfetamine—Somnolence—Gabapentin—epilepsy syndrome	3.6e-05	0.000348	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Valproic Acid—epilepsy syndrome	3.6e-05	0.000348	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Gabapentin—epilepsy syndrome	3.57e-05	0.000345	CcSEcCtD
Lisdexamfetamine—Anxiety—Topiramate—epilepsy syndrome	3.55e-05	0.000343	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	3.53e-05	0.000342	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Gabapentin—epilepsy syndrome	3.52e-05	0.000341	CcSEcCtD
Lisdexamfetamine—Urticaria—Pregabalin—epilepsy syndrome	3.51e-05	0.000339	CcSEcCtD
Lisdexamfetamine—Asthenia—Valproic Acid—epilepsy syndrome	3.51e-05	0.000339	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	3.5e-05	0.000338	CcSEcCtD
Lisdexamfetamine—Fatigue—Gabapentin—epilepsy syndrome	3.49e-05	0.000338	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Pregabalin—epilepsy syndrome	3.49e-05	0.000338	CcSEcCtD
Lisdexamfetamine—Dry mouth—Topiramate—epilepsy syndrome	3.48e-05	0.000336	CcSEcCtD
Lisdexamfetamine—Constipation—Gabapentin—epilepsy syndrome	3.47e-05	0.000335	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Valproic Acid—epilepsy syndrome	3.35e-05	0.000323	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Topiramate—epilepsy syndrome	3.34e-05	0.000323	CcSEcCtD
Lisdexamfetamine—Tachycardia—Topiramate—epilepsy syndrome	3.33e-05	0.000322	CcSEcCtD
Lisdexamfetamine—Skin disorder—Topiramate—epilepsy syndrome	3.31e-05	0.00032	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Topiramate—epilepsy syndrome	3.3e-05	0.000319	CcSEcCtD
Lisdexamfetamine—Amphetamine—CYP2D6—epilepsy syndrome	3.29e-05	0.0139	CrCbGaD
Lisdexamfetamine—Hypersensitivity—Pregabalin—epilepsy syndrome	3.26e-05	0.000315	CcSEcCtD
Lisdexamfetamine—Anorexia—Topiramate—epilepsy syndrome	3.25e-05	0.000314	CcSEcCtD
Lisdexamfetamine—Dizziness—Valproic Acid—epilepsy syndrome	3.23e-05	0.000313	CcSEcCtD
Lisdexamfetamine—Urticaria—Gabapentin—epilepsy syndrome	3.22e-05	0.000311	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Gabapentin—epilepsy syndrome	3.2e-05	0.00031	CcSEcCtD
Lisdexamfetamine—Asthenia—Pregabalin—epilepsy syndrome	3.17e-05	0.000307	CcSEcCtD
Lisdexamfetamine—Vomiting—Valproic Acid—epilepsy syndrome	3.11e-05	0.000301	CcSEcCtD
Lisdexamfetamine—Insomnia—Topiramate—epilepsy syndrome	3.08e-05	0.000298	CcSEcCtD
Lisdexamfetamine—Rash—Valproic Acid—epilepsy syndrome	3.08e-05	0.000298	CcSEcCtD
Lisdexamfetamine—Dermatitis—Valproic Acid—epilepsy syndrome	3.08e-05	0.000298	CcSEcCtD
Lisdexamfetamine—Headache—Valproic Acid—epilepsy syndrome	3.06e-05	0.000296	CcSEcCtD
Lisdexamfetamine—Methamphetamine—CYP2D6—epilepsy syndrome	3.05e-05	0.0129	CrCbGaD
Lisdexamfetamine—Dyspnoea—Topiramate—epilepsy syndrome	3.04e-05	0.000294	CcSEcCtD
Lisdexamfetamine—Somnolence—Topiramate—epilepsy syndrome	3.03e-05	0.000293	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Pregabalin—epilepsy syndrome	3.02e-05	0.000292	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Topiramate—epilepsy syndrome	3e-05	0.00029	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Gabapentin—epilepsy syndrome	2.99e-05	0.000289	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Topiramate—epilepsy syndrome	2.96e-05	0.000287	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Topiramate—epilepsy syndrome	2.94e-05	0.000285	CcSEcCtD
Lisdexamfetamine—Fatigue—Topiramate—epilepsy syndrome	2.94e-05	0.000284	CcSEcCtD
Lisdexamfetamine—Dizziness—Pregabalin—epilepsy syndrome	2.92e-05	0.000283	CcSEcCtD
Lisdexamfetamine—Constipation—Topiramate—epilepsy syndrome	2.92e-05	0.000282	CcSEcCtD
Lisdexamfetamine—Asthenia—Gabapentin—epilepsy syndrome	2.91e-05	0.000281	CcSEcCtD
Lisdexamfetamine—Nausea—Valproic Acid—epilepsy syndrome	2.9e-05	0.000281	CcSEcCtD
Lisdexamfetamine—Selegiline—ABCB1—epilepsy syndrome	2.83e-05	0.012	CrCbGaD
Lisdexamfetamine—Vomiting—Pregabalin—epilepsy syndrome	2.81e-05	0.000272	CcSEcCtD
Lisdexamfetamine—Rash—Pregabalin—epilepsy syndrome	2.79e-05	0.000269	CcSEcCtD
Lisdexamfetamine—Dermatitis—Pregabalin—epilepsy syndrome	2.78e-05	0.000269	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Gabapentin—epilepsy syndrome	2.77e-05	0.000268	CcSEcCtD
Lisdexamfetamine—Headache—Pregabalin—epilepsy syndrome	2.77e-05	0.000268	CcSEcCtD
Lisdexamfetamine—Urticaria—Topiramate—epilepsy syndrome	2.71e-05	0.000262	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Topiramate—epilepsy syndrome	2.7e-05	0.000261	CcSEcCtD
Lisdexamfetamine—Dizziness—Gabapentin—epilepsy syndrome	2.68e-05	0.000259	CcSEcCtD
Lisdexamfetamine—Nausea—Pregabalin—epilepsy syndrome	2.63e-05	0.000254	CcSEcCtD
Lisdexamfetamine—Vomiting—Gabapentin—epilepsy syndrome	2.58e-05	0.000249	CcSEcCtD
Lisdexamfetamine—Rash—Gabapentin—epilepsy syndrome	2.56e-05	0.000247	CcSEcCtD
Lisdexamfetamine—Dermatitis—Gabapentin—epilepsy syndrome	2.55e-05	0.000247	CcSEcCtD
Lisdexamfetamine—Headache—Gabapentin—epilepsy syndrome	2.54e-05	0.000245	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Topiramate—epilepsy syndrome	2.51e-05	0.000243	CcSEcCtD
Lisdexamfetamine—Asthenia—Topiramate—epilepsy syndrome	2.45e-05	0.000237	CcSEcCtD
Lisdexamfetamine—Nausea—Gabapentin—epilepsy syndrome	2.41e-05	0.000233	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Topiramate—epilepsy syndrome	2.33e-05	0.000226	CcSEcCtD
Lisdexamfetamine—Dizziness—Topiramate—epilepsy syndrome	2.26e-05	0.000218	CcSEcCtD
Lisdexamfetamine—Vomiting—Topiramate—epilepsy syndrome	2.17e-05	0.00021	CcSEcCtD
Lisdexamfetamine—Rash—Topiramate—epilepsy syndrome	2.15e-05	0.000208	CcSEcCtD
Lisdexamfetamine—Dermatitis—Topiramate—epilepsy syndrome	2.15e-05	0.000208	CcSEcCtD
Lisdexamfetamine—Headache—Topiramate—epilepsy syndrome	2.14e-05	0.000207	CcSEcCtD
Lisdexamfetamine—Nausea—Topiramate—epilepsy syndrome	2.03e-05	0.000196	CcSEcCtD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—PRKCB—epilepsy syndrome	1.86e-05	0.000342	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GRM2—epilepsy syndrome	1.85e-05	0.000341	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—AGT—epilepsy syndrome	1.85e-05	0.00034	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR7—epilepsy syndrome	1.84e-05	0.000339	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ABCG2—epilepsy syndrome	1.84e-05	0.000338	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CCR3—epilepsy syndrome	1.83e-05	0.000337	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ATP2A2—epilepsy syndrome	1.79e-05	0.00033	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—NPY—epilepsy syndrome	1.78e-05	0.000329	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC6A1—epilepsy syndrome	1.78e-05	0.000328	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—HMOX1—epilepsy syndrome	1.77e-05	0.000327	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—AVP—epilepsy syndrome	1.76e-05	0.000324	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—epilepsy syndrome	1.74e-05	0.000321	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CXCL2—epilepsy syndrome	1.72e-05	0.000317	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CRH—epilepsy syndrome	1.72e-05	0.000317	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CCL3—epilepsy syndrome	1.72e-05	0.000317	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—OXT—epilepsy syndrome	1.72e-05	0.000317	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ABCB1—epilepsy syndrome	1.7e-05	0.000314	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GRM2—epilepsy syndrome	1.68e-05	0.00031	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—SSTR3—epilepsy syndrome	1.67e-05	0.000309	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—epilepsy syndrome	1.65e-05	0.000304	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ABCG2—epilepsy syndrome	1.63e-05	0.0003	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—SSTR1—epilepsy syndrome	1.6e-05	0.000296	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CCR8—epilepsy syndrome	1.6e-05	0.000296	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—ARHGEF9—epilepsy syndrome	1.6e-05	0.000296	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—NPY2R—epilepsy syndrome	1.6e-05	0.000296	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CCR9—epilepsy syndrome	1.6e-05	0.000296	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ATP2A2—epilepsy syndrome	1.58e-05	0.000292	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GRM3—epilepsy syndrome	1.57e-05	0.00029	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GRM4—epilepsy syndrome	1.57e-05	0.00029	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—SST—epilepsy syndrome	1.56e-05	0.000287	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CCR2—epilepsy syndrome	1.56e-05	0.000287	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—AVP—epilepsy syndrome	1.55e-05	0.000285	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—SSTR2—epilepsy syndrome	1.54e-05	0.000285	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—CCR5—epilepsy syndrome	1.54e-05	0.000283	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—ADRA2A—epilepsy syndrome	1.52e-05	0.000281	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—PLAT—epilepsy syndrome	1.52e-05	0.00028	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—SSTR3—epilepsy syndrome	1.52e-05	0.00028	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6ST—epilepsy syndrome	1.52e-05	0.00028	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR2A—epilepsy syndrome	1.5e-05	0.000277	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PRICKLE1—epilepsy syndrome	1.5e-05	0.000276	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PRDM4—epilepsy syndrome	1.5e-05	0.000276	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GRM8—epilepsy syndrome	1.49e-05	0.000275	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—AKT1—epilepsy syndrome	1.47e-05	0.000271	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CXCL12—epilepsy syndrome	1.46e-05	0.00027	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—BDKRB2—epilepsy syndrome	1.46e-05	0.00027	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—ARHGEF9—epilepsy syndrome	1.46e-05	0.000269	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—NPY2R—epilepsy syndrome	1.46e-05	0.000269	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CCR8—epilepsy syndrome	1.46e-05	0.000269	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—SSTR1—epilepsy syndrome	1.46e-05	0.000269	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CCR9—epilepsy syndrome	1.46e-05	0.000269	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC2A1—epilepsy syndrome	1.45e-05	0.000267	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CNR1—epilepsy syndrome	1.44e-05	0.000265	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GRM4—epilepsy syndrome	1.43e-05	0.000263	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GRM3—epilepsy syndrome	1.43e-05	0.000263	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—OPRD1—epilepsy syndrome	1.42e-05	0.000262	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—PRKCB—epilepsy syndrome	1.42e-05	0.000262	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—ALB—epilepsy syndrome	1.41e-05	0.00026	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—SSTR2—epilepsy syndrome	1.4e-05	0.000259	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—HTR7—epilepsy syndrome	1.4e-05	0.000258	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—AKT1—epilepsy syndrome	1.38e-05	0.000255	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CHRM1—epilepsy syndrome	1.36e-05	0.000252	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CCR7—epilepsy syndrome	1.36e-05	0.000252	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GRM1—epilepsy syndrome	1.36e-05	0.000252	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PDYN—epilepsy syndrome	1.36e-05	0.000252	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GRM8—epilepsy syndrome	1.35e-05	0.00025	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—PLAT—epilepsy syndrome	1.35e-05	0.000248	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCR5—epilepsy syndrome	1.32e-05	0.000243	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ACKR4—epilepsy syndrome	1.31e-05	0.000241	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GNAO1—epilepsy syndrome	1.29e-05	0.000238	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—OPRD1—epilepsy syndrome	1.29e-05	0.000238	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—epilepsy syndrome	1.29e-05	0.000238	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC2A1—epilepsy syndrome	1.29e-05	0.000237	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GAL—epilepsy syndrome	1.28e-05	0.000236	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GRM5—epilepsy syndrome	1.27e-05	0.000234	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CHRM3—epilepsy syndrome	1.27e-05	0.000234	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—ALB—epilepsy syndrome	1.25e-05	0.00023	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CCR7—epilepsy syndrome	1.24e-05	0.000228	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GRM1—epilepsy syndrome	1.24e-05	0.000228	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CHRM1—epilepsy syndrome	1.24e-05	0.000228	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PDYN—epilepsy syndrome	1.24e-05	0.000228	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—AGT—epilepsy syndrome	1.22e-05	0.000225	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—HMOX1—epilepsy syndrome	1.19e-05	0.00022	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—BDKRB1—epilepsy syndrome	1.19e-05	0.00022	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CHRM2—epilepsy syndrome	1.19e-05	0.00022	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SSTR5—epilepsy syndrome	1.18e-05	0.000218	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SSTR4—epilepsy syndrome	1.18e-05	0.000218	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—AVP—epilepsy syndrome	1.18e-05	0.000218	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—AVP—epilepsy syndrome	1.18e-05	0.000217	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GAL—epilepsy syndrome	1.16e-05	0.000215	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GABBR1—epilepsy syndrome	1.16e-05	0.000214	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GRM5—epilepsy syndrome	1.15e-05	0.000212	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CHRM3—epilepsy syndrome	1.15e-05	0.000212	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ABCB1—epilepsy syndrome	1.15e-05	0.000211	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCR10—epilepsy syndrome	1.14e-05	0.000209	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—HRH3—epilepsy syndrome	1.11e-05	0.000205	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CX3CR1—epilepsy syndrome	1.1e-05	0.000204	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—OPRM1—epilepsy syndrome	1.09e-05	0.000202	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CHRM2—epilepsy syndrome	1.08e-05	0.0002	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—BDKRB1—epilepsy syndrome	1.08e-05	0.0002	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CX3CL1—epilepsy syndrome	1.08e-05	0.0002	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ALB—epilepsy syndrome	1.06e-05	0.000196	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—HMOX1—epilepsy syndrome	1.06e-05	0.000195	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GABBR1—epilepsy syndrome	1.05e-05	0.000194	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—AVP—epilepsy syndrome	1.05e-05	0.000193	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CCR3—epilepsy syndrome	1.03e-05	0.000191	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—POMC—epilepsy syndrome	1.03e-05	0.00019	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ABCB1—epilepsy syndrome	1.01e-05	0.000187	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HRH3—epilepsy syndrome	1.01e-05	0.000186	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—NPY—epilepsy syndrome	1.01e-05	0.000186	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCL2—epilepsy syndrome	1.01e-05	0.000186	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CCR5—epilepsy syndrome	1e-05	0.000185	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—OPRM1—epilepsy syndrome	9.94e-06	0.000183	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GRM2—epilepsy syndrome	9.93e-06	0.000183	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—HTR2A—epilepsy syndrome	9.81e-06	0.000181	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CXCL2—epilepsy syndrome	9.72e-06	0.000179	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CRH—epilepsy syndrome	9.72e-06	0.000179	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—OXT—epilepsy syndrome	9.72e-06	0.000179	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CCR3—epilepsy syndrome	9.39e-06	0.000173	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—AGT—epilepsy syndrome	9.31e-06	0.000172	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—NPY—epilepsy syndrome	9.15e-06	0.000169	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SSTR3—epilepsy syndrome	8.98e-06	0.000166	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CXCL2—epilepsy syndrome	8.83e-06	0.000163	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—OXT—epilepsy syndrome	8.83e-06	0.000163	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CRH—epilepsy syndrome	8.83e-06	0.000163	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CCL3—epilepsy syndrome	8.83e-06	0.000163	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—SST—epilepsy syndrome	8.79e-06	0.000162	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CCR2—epilepsy syndrome	8.79e-06	0.000162	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ST3GAL3—epilepsy syndrome	8.78e-06	0.000162	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ARHGEF9—epilepsy syndrome	8.61e-06	0.000159	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SSTR1—epilepsy syndrome	8.61e-06	0.000159	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCR8—epilepsy syndrome	8.61e-06	0.000159	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NPY2R—epilepsy syndrome	8.61e-06	0.000159	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCR9—epilepsy syndrome	8.61e-06	0.000159	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—ADRA2A—epilepsy syndrome	8.6e-06	0.000159	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GRM3—epilepsy syndrome	8.44e-06	0.000156	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GRM4—epilepsy syndrome	8.44e-06	0.000156	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—DUSP4—epilepsy syndrome	8.28e-06	0.000153	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SSTR2—epilepsy syndrome	8.28e-06	0.000153	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CXCL12—epilepsy syndrome	8.26e-06	0.000152	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—BDKRB2—epilepsy syndrome	8.26e-06	0.000152	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CNR1—epilepsy syndrome	8.11e-06	0.00015	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PLCB1—epilepsy syndrome	8.08e-06	0.000149	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GRM8—epilepsy syndrome	8e-06	0.000148	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PGF—epilepsy syndrome	8e-06	0.000148	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CCR2—epilepsy syndrome	7.98e-06	0.000147	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—SST—epilepsy syndrome	7.98e-06	0.000147	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—HTR7—epilepsy syndrome	7.91e-06	0.000146	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—POMC—epilepsy syndrome	7.83e-06	0.000144	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—ADRA2A—epilepsy syndrome	7.81e-06	0.000144	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CCL2—epilepsy syndrome	7.67e-06	0.000141	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GNAO1—epilepsy syndrome	7.63e-06	0.000141	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—OPRD1—epilepsy syndrome	7.63e-06	0.000141	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AKT3—epilepsy syndrome	7.54e-06	0.000139	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CXCL12—epilepsy syndrome	7.51e-06	0.000138	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—BDKRB2—epilepsy syndrome	7.51e-06	0.000138	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CNR1—epilepsy syndrome	7.37e-06	0.000136	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PLCB1—epilepsy syndrome	7.34e-06	0.000135	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CHRM1—epilepsy syndrome	7.32e-06	0.000135	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PDYN—epilepsy syndrome	7.32e-06	0.000135	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCR7—epilepsy syndrome	7.32e-06	0.000135	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GRM1—epilepsy syndrome	7.32e-06	0.000135	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HTR7—epilepsy syndrome	7.19e-06	0.000133	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ALB—epilepsy syndrome	7.17e-06	0.000132	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HBEGF—epilepsy syndrome	6.98e-06	0.000129	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CDC42—epilepsy syndrome	6.88e-06	0.000127	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GAL—epilepsy syndrome	6.88e-06	0.000127	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GFAP—epilepsy syndrome	6.88e-06	0.000127	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AKT3—epilepsy syndrome	6.85e-06	0.000126	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CASP2—epilepsy syndrome	6.8e-06	0.000125	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CHRM3—epilepsy syndrome	6.8e-06	0.000125	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GRM5—epilepsy syndrome	6.8e-06	0.000125	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AVP—epilepsy syndrome	6.66e-06	0.000123	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CX3CR1—epilepsy syndrome	6.52e-06	0.00012	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—BDKRB1—epilepsy syndrome	6.4e-06	0.000118	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CX3CL1—epilepsy syndrome	6.4e-06	0.000118	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CHRM2—epilepsy syndrome	6.4e-06	0.000118	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ALB—epilepsy syndrome	6.35e-06	0.000117	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CDC42—epilepsy syndrome	6.25e-06	0.000115	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GABBR1—epilepsy syndrome	6.22e-06	0.000115	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AVP—epilepsy syndrome	6.05e-06	0.000112	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HRH3—epilepsy syndrome	5.97e-06	0.00011	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—OPRM1—epilepsy syndrome	5.87e-06	0.000108	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CCR5—epilepsy syndrome	5.66e-06	0.000104	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCR3—epilepsy syndrome	5.55e-06	0.000102	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—HTR2A—epilepsy syndrome	5.54e-06	0.000102	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NPY—epilepsy syndrome	5.4e-06	9.97e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ATP2A2—epilepsy syndrome	5.4e-06	9.97e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AGT—epilepsy syndrome	5.26e-06	9.7e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HSPB1—epilepsy syndrome	5.21e-06	9.61e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—OXT—epilepsy syndrome	5.21e-06	9.61e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CRH—epilepsy syndrome	5.21e-06	9.61e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CXCL2—epilepsy syndrome	5.21e-06	9.61e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCL3—epilepsy syndrome	5.21e-06	9.61e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CCR5—epilepsy syndrome	5.14e-06	9.48e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HTR2A—epilepsy syndrome	5.03e-06	9.28e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PRKCB—epilepsy syndrome	4.86e-06	8.96e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTK2B—epilepsy syndrome	4.85e-06	8.94e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TSC1—epilepsy syndrome	4.85e-06	8.94e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AGT—epilepsy syndrome	4.78e-06	8.81e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCR2—epilepsy syndrome	4.72e-06	8.69e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SST—epilepsy syndrome	4.72e-06	8.69e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NTRK2—epilepsy syndrome	4.72e-06	8.69e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—DUSP6—epilepsy syndrome	4.67e-06	8.62e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ADRA2A—epilepsy syndrome	4.61e-06	8.51e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PLAT—epilepsy syndrome	4.6e-06	8.47e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—BDKRB2—epilepsy syndrome	4.43e-06	8.17e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CXCL12—epilepsy syndrome	4.43e-06	8.17e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—POMC—epilepsy syndrome	4.43e-06	8.16e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PRKCB—epilepsy syndrome	4.41e-06	8.14e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL6ST—epilepsy syndrome	4.4e-06	8.1e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—JUNB—epilepsy syndrome	4.35e-06	8.02e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CNR1—epilepsy syndrome	4.35e-06	8.02e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PLCB1—epilepsy syndrome	4.34e-06	8e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HTR7—epilepsy syndrome	4.25e-06	7.83e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HBEGF—epilepsy syndrome	4.12e-06	7.6e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AKT3—epilepsy syndrome	4.05e-06	7.46e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—POMC—epilepsy syndrome	4.02e-06	7.41e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ADAM10—epilepsy syndrome	3.95e-06	7.29e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CCL2—epilepsy syndrome	3.93e-06	7.25e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—S100B—epilepsy syndrome	3.74e-06	6.89e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SOCS3—epilepsy syndrome	3.7e-06	6.82e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CDC42—epilepsy syndrome	3.69e-06	6.81e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AVP—epilepsy syndrome	3.57e-06	6.59e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HES1—epilepsy syndrome	3.38e-06	6.23e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FYN—epilepsy syndrome	3.29e-06	6.06e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—H2AFX—epilepsy syndrome	3.27e-06	6.04e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MEF2C—epilepsy syndrome	3.27e-06	6.03e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—YWHAZ—epilepsy syndrome	3.16e-06	5.82e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NGF—epilepsy syndrome	3.12e-06	5.76e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCR5—epilepsy syndrome	3.04e-06	5.6e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HTR2A—epilepsy syndrome	2.97e-06	5.48e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TSC2—epilepsy syndrome	2.83e-06	5.21e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AGT—epilepsy syndrome	2.82e-06	5.2e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—APOE—epilepsy syndrome	2.76e-06	5.1e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KDR—epilepsy syndrome	2.71e-06	4.99e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PRKCB—epilepsy syndrome	2.61e-06	4.81e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL6ST—epilepsy syndrome	2.6e-06	4.79e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—POMC—epilepsy syndrome	2.37e-06	4.38e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCL2—epilepsy syndrome	2.32e-06	4.28e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FGF2—epilepsy syndrome	2.1e-06	3.87e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RELA—epilepsy syndrome	1.95e-06	3.59e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MTOR—epilepsy syndrome	1.91e-06	3.52e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AKT1—epilepsy syndrome	1.77e-06	3.27e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CASP3—epilepsy syndrome	1.76e-06	3.24e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—JUN—epilepsy syndrome	1.71e-06	3.15e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MMP9—epilepsy syndrome	1.66e-06	3.06e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AKT1—epilepsy syndrome	1.61e-06	2.97e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SRC—epilepsy syndrome	1.53e-06	2.82e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—VEGFA—epilepsy syndrome	1.49e-06	2.75e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AKT1—epilepsy syndrome	9.52e-07	1.76e-05	CbGpPWpGaD
